logo-loader
RNS
ValiRx PLC

ValiRx PLC - Result of AGM, Warrants & Directorate Change

RNS Number : 8598M
ValiRx PLC
17 July 2026
 

17 July 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

Result of AGM & Issue of Warrants

Director and PDMR Shareholding

Directorate Change

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

Details of the votes received will be available on the Company's website shortly.

Issue of Warrants

Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 577,500,000 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.28 pence per Ordinary Share and are exercisable at any time until the third anniversary of date of grant.

In addition, the Company has issued 53,750,000 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of date of grant.

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7.00 a.m. on 15 May 2026.

Directorate Change

The Company announces that Cathy Tralau-Stewart did not stand for re-election as a Non-Executive Director at the Company's AGM held earlier today. Accordingly, following the conclusion of the AGM, Cathy has stepped down from the Board with immediate effect.

The Board would like to thank Cathy for her valuable contribution to the Company during her tenure and wishes her every success in the future.

Cathy Tralau-Stewart commented:

"I am committed to supporting the broader translation of academic science to patients and as such I think my time is best spent focusing on my leadership of the Milner Therapeutics Institute, University of Cambridge.

I am confident in the current management and scientific teams and that focusing the portfolio on later stage pre-clinical projects is important for the Company to deliver for shareholders.

I wish ValiRx and the team the best for the future."

Martin Gouldstone, Non-Executive Chairman of ValiRx commented:

"On behalf of the Board of VAL plc I would like to say a big thank you to Cathy for her scientific leadership in both her roles as CSO and more recently on the Board. Cathy leaves VAL in a much stronger position scientifically. We wish her well as she concentrates on her executive role at the Milner Therapeutics Institute."

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here:  https://valirx.com/s/cc8ef3

For more information, please contact:

 

Investor questions on this announcement

We encourage all investors to share questions

on this announcement via our investor hub

https://valirx.com/link/yzY60P

ValiRx plc

Dr Mark Eccleston, CEO

Tel: +44 115 784 0026

www.valirx.com

Mark.Eccleston@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Shard Capital Partners LLP (Sole Broker)

Damon Heath

Tel: +44 (0) 20 7186 9000

V Formation (Public Relations)

Jocelyn Braithwaite

+44 (0) 115 646 5491

 www.vformation.co.uk/jocelyn@vformation.co.uk

 

Subscribe to our news alert service: https://valirx.com/s/f298d1

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Mark Eccleston

 

2

Reason for notification


a.

Position/Status

Director

 

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

Warrants as part of the Fundraising

c.

Price(s) and volume(s)







Price(s)

Volume(s)


0.28 pence

25,000,000



d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

17 July 2026

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Gerry Desler

2

Reason for notification


a.

Position/Status

Director

 

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

Warrants as part of the Fundraising

c.

Price(s) and volume(s)







Price(s)

Volume(s)


0.28 pence

2,500,000



d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

17 July 2026

f.

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFFLDFIDLIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read